Tag: Business Wire

  • $87 Billion Worldwide Cannabis Industry to 2027 – Featuring Aurora Cannabis, Cannabis Science, CannTrust Holdings and Cronos Among Others – ResearchAndMarkets.com

    DUBLIN–(BUSINESS WIRE)–The “Global Cannabis Market (2022-2027) by Form, Product Type, Compound, Source, Distribution Channel, Application, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.

    The Global Cannabis Market is estimated to be USD 25.74 Bn in 2022 and is expected to reach USD 87.17 Bn by 2027, growing at a CAGR of 27.63%

    Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

    As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding growth and reducing risks.

    Competitive Quadrant

    The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

    Ansoff Analysis

    The report presents a detailed Ansoff matrix analysis for the Global Cannabis Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

    The analyst analyses the Global Cannabis Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

    Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

    Why buy this report?

    • The report offers a comprehensive evaluation of the Global Cannabis Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
    • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
    • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
    • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
    • The report also contains a competitive analysis using Positioning Quadrants, the analyst’s competitive positioning tool.

    Market Dynamics

    Drivers

    • Social Acceptance of Cannabis Products Globally
    • Increasing Use in Treatment of the Patients Diagnosed with Neurological Disorders and other Chronic Diseases
    • Legal Supply of Quality-controlled Cannabis Available for Sale
    • Increasing Demand of Cannabis-infus

    Restraints

    • Lacking Guidance and Inaccurate Dosing can Result in Dangerous Consequences
    • Product Developers Need to Be Constantly on Their Toes
    • Governance of Cannabis Possession, Usage, Distribution or Sales by International Laws

    Opportunities

    • New Product Development Related to Cannabis-infused Foods and Beverages
    • Pharmaceutical and Beverage Companies Eyeing the Cannabis Market for Long-Term Gain
    • Efficient Cannabis Retractation Procedures Under Development

    Challenges

    • Heavy Taxes Imposed on Cannabis Industry
    • Intensive Energy Consumption and Maintaining Product Consistency for the Cultivation of Cannabis

    Market Segmentation

    The Global Cannabis Market is segmented based on Form, Product Type, Compound, Source, Distribution Channel, Application, and Geography.

    • By Form, the market is classified into Concentrated Oil, Cream, Food Additive, Inhaled Liquids, Supplement Capsule and Tincture Spray.
    • By Product Type, the market is classified into Concentrates, Flower, leaves and Seeds.
    • By Compound, the market is classified into Balanced THC & CBD, Cannabidiol (CBD)-Dominant and Tetrahydrocannabinol (THC)-Dominant.
    • By Source, the market is classified into Non-Organic and Organic.
    • By Distribution Channel, the market is classified into Offline and Online.
    • By Application, the market is classified into Cosmetics & Personal Care, Food & Beverage, Medical & Pharmaceuticals, Pet Care and Recreational.
    • By Geography, the market is classified into Americas, Europe, Middle East & Africa, and Asia-Pacific.

    Companies Mentioned

    • Acreage Holdings
    • Aurora Cannabis, Inc.
    • Cannabis Science, Inc.
    • CannTrust Holdings, Inc.
    • Canopy Growth Corp.
    • Cronos Group
    • Curaleaf Holdings, Inc.
    • CV Sciences, Inc.
    • Green Thumb Industries, Inc.
    • Harvest Health & Recreation, Inc.
    • HEXO Operations, Inc.
    • Jazz Pharmaceuticals, Inc.
    • Medical Marijuana, Inc.
    • MedMen
    • Organigram Holdings,Inc.
    • STENOCARE A/S
    • Tikun Olam, LLC
    • Tilray, Inc.
    • Trulieve Cannabis
    • Vivo Cannabis, Inc.

    For more information about this report visit https://www.researchandmarkets.com/r/pu71k7

    Contacts

    ResearchAndMarkets.com

    Laura Wood, Senior Press Manager

    press@researchandmarkets.com

    For E.S.T Office Hours Call 1-917-300-0470

    For U.S./ CAN Toll Free Call 1-800-526-8630

    For GMT Office Hours Call +353-1-416-8900

  • Global Omega 3 Market: Myriad Health Benefits Driving Billion Dollar Industry – ResearchAndMarkets.com

    DUBLIN–(BUSINESS WIRE)–The “Global Omega 3 Market: Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.

    Omega 3 fatty acids come in three major forms: eicosapentaenoic acid (EPA), alpha-linoleic acid (ALA) and docosahexaenoic acid (DHA). EPA and DHA are mostly found in marine animals like fatty fish and krill and are majorly promoted for their benefit to the heart. While ALA is found in plant seed oils such as walnuts, flaxseed, hemp. Out of the two the animal based variety i.e. EPA and DHA is promoted more as most health benefits are linked to it.

    EPA and DHA can help to reduce several cardiovascular disease risk factors and many experts recommend the consumption of omega-3s to support heart health. DHA is considered to be important for visual and neurological development in infants. Research has also demonstrated that poor memory is associated with low levels of DHA and DHA supplements support brain health in ageing brains. It also supports health of the eyes, as DHA is the raw material that help to prevent retinal cell damage.

    In recent years due to increased focus on omega 3 fatty acids health benefits it has become a multibillion-dollar business, with Americans alone spending more than 2 billion dollars on foods fortified with omega-3 fats. As research and awareness continues to increase, the consumption of omega 3 fatty acids is expected to rise. Also, the global omega-3 nutrition gap is far from covered. Cardiovascular health benefits is the major driver and supplements providing this are projected to have a market value of about 8 billion dollars by 2018. The opportunity for supplements aiming brain and vision improvement is valued more than $500 million by 2018. Supplements is not the only form in which omega-3 fatty acids are available, in fact in recent years packaged food and drinks rich in omega-3 fatty acids have had a higher growth rate than supplements.

    In 2021, marine source accounted for the largest share of the market and projected to maintain its dominance over the forecast period. Krill and fish oils are two major marine sources for omega-3 fatty acid. The availability of various types of fishes and the numerous health benefits offered by them is projected to be the major factor driving the market growth. Krill comprises the largest biomass on the earth, which ensure availability of the raw material source for krill oil.

    However, owing to shift in trend towards non animal based supplements is projected to restrain the growth of the market. Furthermore, owing to rise in manufacturing expense due to presence of toxins along with decrease production is projected to restrict the utilization of fish oil in this industry. Other sources such as nuts and seeds, vegetable oils and soya and soya products are likely to have a positive impact on the market.

    Omega 3 are used in various applications. Among all the applications dietary supplements segment accounted for the largest share of the market. More than 50% of the market is accounted by dietary supplement segment. This segment is witnessing growth on account of increasing importance of omega 3 supplements. Infant formula segment is projected to witness significant growth on account of rising importance of ALA for the functional development of infants during pregnancy and first two years after childbirth. Moreover, governments are educating people, especially in emerging economies about the importance of infant health, which is further projected to fuel the growth. Food and beverages segment is projected to witness growth on account of rising demand for new health products, R&D initiative by the food manufacturers, advancement in the field of emulsification technologies and encapsulation.

    Market Segmentation

    Type

    • ALA (alpha-linolenic acid)
    • DHA (docosahexaenoic acid)
    • EPA (eicosapentaenoic acid)

    Source

    • Marine
    • Nuts and Seeds
    • Vegetable oils
    • Soya and Soya Products

    Application

    • Dietary supplement
    • Pharmaceutical
    • Infant formula
    • Food & Beverages
    • Pet Foods
    • Fish Feed

    Key Topics Covered:

    1. Preface

    2. Executive Summary

    3. Omega 3 Market: Business Outlook & Market Dynamics

    4. Omega 3 Market: by Type, 2020-2030, USD (Million)

    5. Omega 3 Market: by Source, 2020-2030, USD (Million)

    6. Omega 3 Market: by Application, 2020-2030, USD (Million)

    7. North America Omega 3 Market, 2020-2030, USD (Million)

    8. UK and European Union Omega 3 Market, 2020-2030, USD (Million)

    9. Asia Pacific Omega 3 Market, 2020-2030, USD (Million)

    10. Latin America Omega 3 Market, 2020-2030, USD (Million)

    11. Middle East and Africa Omega 3 Market, 2020-2030, USD (Million)

    12. Company Profiles

    Companies Mentioned

    • Cargill Ltd.
    • Croda International PLC.
    • FMC Corporation
    • GC Reiber Oils
    • LUHUA BIOMARINE (Shadong) Co Ltd
    • Royal DSM
    • Pharma Marine AS
    • Omega Protein Corporation
    • Polaris
    • Olvea Fish Oils.

    For more information about this report visit https://www.researchandmarkets.com/r/4kjln7

    Contacts

    ResearchAndMarkets.com

    Laura Wood, Senior Press Manager

    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470

    For U.S./ CAN Toll Free Call 1-800-526-8630

    For GMT Office Hours Call +353-1-416-8900

  • 2022 Private Label Beverages and Contract Packing in the U.S. – ResearchAndMarkets.com

    DUBLIN–(BUSINESS WIRE)–The “2022 Private Label Beverages and Contract Packing in the U.S.” report from Beverage Marketing has been added to ResearchAndMarkets.com’s offering.

    Get behind the scenes for an in-depth look at private label and co-packing trends and issues, plus get the low-down on capabilities of players in the co-packing industry. This research report from Beverage Marketing Corporation offers insight into private label beverage market production, quantifies the private label vs. branded market, offers representative pricing, sheds light on issues related to contract packing and discusses the trends affecting the private label and contract packing industry. It includes an extensive contract packing directory, providing contact information for co-packers and details on their product, process and production capabilities.

    The answers you need

    Private Label Beverages and Contract Packing in the U.S. is suitable for those seeking a comprehensive understanding of the market for private label products and contract packing, those seeking a contract packer for their beverage product, suppliers who sell product to contract bottlers or anyone requiring a better understanding of the specific processing capabilities of contract bottling operations.

    • How is the market for private label beverages performing?
    • What trends are shaping the private label industry?
    • Who can co-pack my products?
    • What private label categories are growing the fastest?
    • What are the pricing trends in contract packing?
    • Which contract packers have the right product and processing capabilities for my brand?

    This private label and contract packing research report features

    The report features a comprehensive analysis of the market for private label products as well as a look at the behind the scenes issues involved in contract bottling. It also includes a section devoted to performance of private label beverages and key manufacturers operating in this arena including the factors driving their performance. Contract packing trends and agreements are also discussed and a sample co-packing agreement is provided.

    Additionally, the report features a directory of contract packers which serves as a resource for those in need of contract packing services or those who act as suppliers to the contract packing industry.

    This unique and incredibly useful report includes:

    • Historical and current data on the overall private label category with specific detail on the private label market for beverages.
    • An overview of the major suppliers of private label beverages in the U.S. including Refresco, Dairy Farmers of America, Louis Dreyfus Citrus, Niagara Bottling and others.
    • Trends in contract packing by beverage category and a discussion of key issues.
    • Average pricing of contract packing for conversion only as well as full product contracts and full-product cost makeup and contract packing contract issues. Includes a sample contract.
    • A beverage contract packer list / indexed directory featuring contact information, product and processing capabilities, # of hot and cold fill lines, label specifications, capping capabilities and more.
    • Contract fillers’ product production capabilities across a broad range of beverage categories including carbonated soft drinks, dairy, beer, bottled water, wine and spirits based beverages, nutritional beverages, cocktail mixes, frozen concentrates, every drinks, energy shots, enhanced waters, cannabis drinks, fruit beverages and more.
    • Indication of contract fillers ability to address various processing requirements including hot fill, cold fill, aseptic, HPP, HYPA, heat sealed, ambient and carbonation, cross-referenced by capabilities for filling various packaging types including PET, HDPE, paperboard, can, aseptic, glass, pouch, polypropylene, aluminum, kegs and many more.
    • Indexed by location, product, process capabilities and more for easy access to packers meeting the right specifications.

    Key Topics Covered:

    1. CURRENT TRENDS IN PRIVATE LABEL

    • The Private Label Industry
    • Overview
    • Supplier Capabilities
    • The Private Label Industry by Distribution Channel
    • Overview
    • Supermarkets
    • Drug Stores
    • Convenience/Gas

    2. PRIVATE LABEL BEVERAGES BY CATEGORY

    • Private Label Beverages
    • Overview
    • Carbonated Soft Drinks
    • Fruit Beverages
    • Alcoholic Beverages
    • Milk
    • Bottled Water
    • Ready-to-Drink Tea and Coffee
    • Sports and Energy Drinks
    • Dairy Alternatives

    3. MAJOR PRIVATE LABEL BEVERAGE SUPPLIERS

    • Leading Private Label Companies
    • Overview
    • Refresco Group B.V.
    • Overview
    • Marketing
    • Dairy Farmers of America
    • Overview
    • Louis Dreyfus Citrus
    • Overview
    • Niagara Bottling
    • Overview

    4. CURRENT TRENDS IN CONTRACT PACKING

    • The Contract Packing Industry
    • Overview
    • Recent Developments

    5. CONTRACT PACKING BY BEVERAGE CATEGORY

    • Contract Packed Beverages
    • Overview
    • Beer
    • Carbonated Soft Drinks
    • Bottled Water
    • Fruit Beverages
    • Ready-to-Drink Tea and Coffee
    • Sports Drinks

    6. PRICING OF CONTRACT PACKING

    • Contract Packing Pricing
    • Overview
    • Representative Pricing Data
    • Conversion Only
    • Full-Product Contracts
    • Full-Product Cost Estimates
    • Overview

    7. CONTRACT PACKING CONTRACT ISSUES

    • Contract Issues
    • Overview

    8. DIRECTORY OF BEVERAGE CONTRACT PACKERS

    • Beverage Contract Packers

    INDEXES TO DIRECTORY OF BEVERAGE CONTRACT PACKERS

    • Geographical Index
    • Beverage Category Index
    • Production Process Index
    • Personnel Index

    Appendix

    • Beverage Packing Agreements
    • Co-Pack Agreement
    • Manufacturing/Packing Agreement Terms & Conditions

    Companies Mentioned

    • Dairy Farmers of America
    • Louis Dreyfus Citrus
    • Niagara Bottling
    • Refresco Group B.V.

    For more information about this report visit https://www.researchandmarkets.com/r/vrm58v

    Contacts

    ResearchAndMarkets.com

    Laura Wood, Senior Press Manager

    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470

    For U.S./ CAN Toll Free Call 1-800-526-8630

    For GMT Office Hours Call +353-1-416-8900

  • The Alkaline Water Company Now Projects $20 Million in Total Cost Savings and Margin Enhancements in its Pathway to Profitability

    The Company Has Identified Approximately $5 Million in Additional Savings, Compared to Fiscal 2022, Once Fully Implemented Through Fiscal Year 2024

    (All amounts are in U.S. dollars)

    SCOTTSDALE, Ariz.–(BUSINESS WIRE)–The Alkaline Water Company Inc. (NASDAQ and CSE: WTER) (the “Company”), the country’s largest independent alkaline water company and the Clean Beverage® company, provided an update today on its Pathway to Profitability, announcing another $5 million in potential costs savings and margin enhancements. Total estimated savings, once fully implemented throughout fiscal years 2023 and 2024, are now approximately $20 million compared to fiscal year 2022. This morning, the Company also announced that it expects to report record revenue of approximately $19.6 million when it files its 10-Q for its second quarter fiscal 2023 next Monday, November 14th, 2022, after market close.

    “The Alkaline Water Company continues to find ways to be more efficient while maintaining strong sales momentum in pursuit of our ultimate goal of becoming a profitable company,” stated Frank Lazaran, President and CEO of The Alkaline Water Company. “We have now identified approximately $20 million in total savings and margin improvement compared to last fiscal year. Though it will take time to see the full benefits of the measures we’re taking to improve our bottom line, we look forward to sharing with our shareholders next week the early progress we’ve made in our first full quarter on our Pathway to Profitability.”

    About The Alkaline Water Company:

    The Alkaline Water Company is the Clean Beverage® company making a difference in the water you drink and the world we share.

    Founded in 2012, The Alkaline Water Company (NASDAQ and CSE: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH alkaline drinking water with trace minerals and electrolytes and boasts our trademarked “Clean Beverage” label. In 2021, The Alkaline Water Company was pleased to welcome Shaquille O’Neal to its board of advisors and to serve as the celebrity brand ambassador for Alkaline88®.

    To purchase The Alkaline Water Company’s products online, visit us at www.alkaline88.com.

    To learn more about The Alkaline Water Company, please visit www.thealkalinewaterco.com or connect with us on Facebook, Twitter, Instagram, or LinkedIn.

    Notice Regarding Forward-Looking Statements

    This news release contains “forward-looking statements.” Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the following: the statements relating to the Company’s projection of $20 million in total cost savings and margin enhancements in its pathway to profitability; the statements relating to the Company’s identification of approximately $5 million in additional savings compared to fiscal 2022, once fully implemented through fiscal year 2024; the statement relating to the Company’s pathway to profitability; the Company’s expectation of record revenue of approximately $19.6 million; the Company’s ultimate goal of becoming a profitable company; that it will take time to see the full benefits of the measures the Company is taking to improve its bottom line.

    The material assumptions supporting these forward-looking statements include, among others, that the Company’s cost-saving and margin enhancement measures will be fully implemented and, once implemented, they will be effective to reduce the Company’s annual expense and enhance the Company’s margin to the extent anticipated by the Company; that the demand for the Company’s products will continue to significantly grow; that the past production capacity of the Company’s co-packing facilities can be maintained or increased; that there will be increased production capacity through implementation of new production facilities, new co-packers and new technology; that there will be an increase in number of products available for sale to retailers and consumers; that there will be an expansion in geographical areas by national retailers carrying the Company’s products; that there will be an expansion into new national and regional grocery retailers; that there will be an expansion into new e-commerce, home delivery, convenience, and healthy food channels; that there will not be interruptions on production of the Company’s products; that there will not be a recall of products due to unintended contamination or other adverse events relating to the Company’s products; and that the Company will be able to obtain additional capital to meet the Company’s growing demand and satisfy the capital expenditure requirements needed to increase production and support sales activity. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, governmental regulations being implemented regarding the production and sale of alkaline water or any other products, including products containing hemp/CBD; the fact that consumers may not embrace and purchase any of the Company’s CBD-infused products; the fact that the Company may not be permitted by the FDA or other regulatory authority to market or sell any of its CBD-infused products; additional competitors selling alkaline water and enhanced water products in bulk containers reducing the Company’s sales; the fact that the Company does not own or operate any of its production facilities and that co-packers may not renew current agreements and/or not satisfy increased production quotas; the fact that the Company has a limited number of suppliers of its unique bulk bottles; the potential for supply-chain interruption due to factors beyond the Company’s control; the fact that there may be a recall of products due to unintended contamination; the inherent uncertainties associated with operating as an early stage company; changes in customer demand and the fact that consumers may not embrace enhanced water products as expected or at all; the extent to which the Company is successful in gaining new long-term relationships with new retailers and retaining existing relationships with retailers; the Company’s ability to raise the additional funding that it will need to continue to pursue its business, planned capital expansion and sales activity; and competition in the industry in which the Company operates and market conditions. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States and Canada. Although the Company believes that any beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Readers should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents the Company files with the SEC, available at www.sec.gov, and on the SEDAR, available at www.sedar.com.

    Contacts

    The Alkaline Water Company Inc.
    Jeff Wright

    Director of Investor Relations

    866-242-0240

    investors@thealkalinewaterco.com

    Media
    Jessica Starman

    888-461-2233

    jessica@elev8newmedia.com

  • Columbia Care Continues Footprint Expansion in Virginia with New Dispensary Opening in Richmond

    Cannabist Carytown is Company’s 5th of 12 Planned Dispensaries; Will Serve Growing Richmond Patient Base

    NEW YORK–(BUSINESS WIRE)–Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and providers of cannabis products in the U.S., announced it has opened Cannabist Carytown on 3100 W Cary Street in Richmond, the Company’s 85th active dispensary nationwide and fifth in Virginia.

    “Virginia has the most patient-accessible program in the country, so we’re proud to make another location available to those who need it,” said Jesse Channon, Chief Growth Officer, Columbia Care. “Virginia’s medical program has grown nearly six times in size in less than two years, which shows an increasing demand in product and the need for more dispensaries. Since the new policy change that took effect July 1, we have seen registration count increase to a base of more than 45,000 patients across the state. The Cannabist retail model offers a welcoming environment for anyone who wants to learn more about the power of this incredible plant.”

    Cannabist Carytown carries a variety of Columbia Care products including Classix and Seed & Strain. Another Cannabist location is expected to open in Williamsburg in the coming weeks, pending Board of Pharmacy approval. Columbia Care and its subsidiary entities, together, are licensed to operate a market-leading total of 12 dispensaries in Virginia. To support this retail footprint, the Company operates nearly 148,000 square feet of cultivation and production capacity and has a fleet of delivery vehicles able to serve the entire state.

    For more information, visit www.gocannabist.com/carytown.

    About Columbia Care

    Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 18 U.S. jurisdictions. Columbia Care operates 131 facilities including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the original multi-state providers of medical cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the company launched Cannabist, its new retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, Amber and Platinum Label CBD. For more information on Columbia Care, please visit www.columbia.care.

    Caution Concerning Forward-Looking Statements

    This press release contains certain statements that constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Forward-looking statements or information contained in this release include, but are not limited to, statements or information with respect to the Company’s ability to execute on retail, wholesale, brand and product initiatives in Virginia. These forward-looking statements or information, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. These risks, uncertainties and other factors include, among others, favorable operating and economic conditions; obtaining and maintaining all required licenses and permits; favorable production levels and sustainable costs from the Company’s operations; and the level of demand for cannabis products, including the Company’s products sold by third parties. In addition, securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Form 10 dated May 9, 2022, filed with the applicable securities regulatory authorities and described from time to time in documents filed by the Company with Canadian and U.S. securities regulatory authorities.

    Contacts

    Investor
    Lee Ann Evans

    Capital Markets

    ir@col-care.com

    Media
    Lindsay Wilson

    Communications

    +1.978.662.2038

    media@col-care.com

  • Mativ Announces Third Quarter 2022 Results

    ALPHARETTA, Ga.–(BUSINESS WIRE)–Mativ Holdings, Inc. (“Mativ” or the “Company”) (NYSE: MATV) reported earnings results for the three month and nine month periods ending September 30, 2022. On July 6, 2022, Schweitzer Mauduit International, Inc. (“SWM”) and Neenah, Inc. (“Neenah”) completed a merger of equals (“the merger”); Financial statements for periods prior to the merger reflect only the legacy SWM results.


    Adjusted measures are reconciled to GAAP at the end of this release. Financial and operating comparisons are versus the prior year period unless stated otherwise. Figures may not sum to total due to rounding. “Organic” is a pro forma non-GAAP measure to reflect acquired/merged companies as if they were owned/merged for the full comparable periods, and adjusted to exclude sales related to assets that have been sold or closed. “Comparable” – is a pro forma non-GAAP measure used to compare current period Mativ results with the combined reported results for legacy Neenah and SWM operations, adjusted for certain reclassifications between the legacy Neenah reporting segments in the prior year.

    Mativ Third Quarter 2022 Highlights

    • Sales increased 76% to $674.1 million with 12% constant currency organic sales growth, or 7% organic growth including negative currency impacts; strong sales growth in release liners, protective solutions, filtration, and paper and specialty packaging led the portfolio
    • GAAP EPS was $(0.43), and included significant expenses related to the Neenah merger closing and integration; Adjusted EPS was $0.74
    • GAAP Operating Loss was $13.9 million; Adjusted Operating Profit was $65.5 million, up 24% on a comparable basis (see non-GAAP reconciliation)
    • Pricing actions across the Company driving top-line gains and offsetting raw material cost increases, with margin expansion across most categories
    • Macro trends such as negative currency changes, increasing global economic uncertainty, and European energy inflation impacted results, as did a cybersecurity incident (unrelated to the integration of the Neenah merger) during the quarter
    • The Company now expects 4Q:22 Adjusted EBITDA to be consistent with 3Q:22 Adjusted EBITDA of $93.0 million and continued year-over-year Adjusted EBITDA growth into 2023
    • The Company still expects net leverage to be at 3.75x or below by year-end with the benefit of enhanced working capital programs, and to be within the 2.5x to 3.5x target range during 2023

    Management Commentary

    Julie Schertell, Chief Executive Officer, commented, “Mativ delivered organic constant currency sales growth of 12% in the quarter, with most business areas delivering increased price, revenue, and margin. On a comparable basis, adjusted operating profits were up nearly 25%. Our merger integration is progressing well and we are executing on our $65 million cost synergy plan. Based on current performance, we now expect to exceed our previously communicated $20 million synergy run-rate exiting 2022.”

    “Despite these positive performance trends, several factors are converging since mid-year to push second half 2022 EBITDA below our original expectations of $210 million to $230 million. Unfavorable currency trends have accelerated and there has been an increase in volatility in the macro backdrop, including global demand uncertainty and inflationary pressures led by the rapid escalation in energy costs, particularly in Europe. Our latest round of pricing actions primarily go into effect late this year and early 2023 and will lag recovery of this rapid increase in energy in the short-term. Additionally, we were also impacted by a cybersecurity incident during the third quarter which temporarily disrupted our operations and reduced sales.”

    Ms. Schertell concluded, “Mativ’s fundamental outlook remains positive despite the current turbulence facing global manufacturers. Looking forward, we expect consistent sequential EBITDA in the fourth quarter, which would represent another period of strong comparable year-over-year growth, and to continue these profit growth trends into 2023 as we trend toward $100 million EBITDA quarters. Our conviction in this outlook is a function of recovering from the cybersecurity incident’s impact on our operating performance, accelerated synergy realization, and additional pricing actions. Furthermore, our synergies provide a valuable offset if macro trends move more unfavorably or recessionary conditions emerge. Our global teams are executing on these near-term cost synergies, as well as laying the foundation for accelerated long-term growth by leveraging the manufacturing technologies, customer relationships, and geographic footprint of our newly merged enterprise.”

    Mativ Third Quarter 2022 Financial Results

    Note: The current period reflects consolidated Mativ results, whereas the prior year period reflects only legacy SWM results. See the “Combined Legacy Financial Information” footnote below and the supplemental tables described therein for additional financial information regarding the combined company’s legacy financial information.

    Advanced Technical Materials (ATM) segment sales were $426.1 million, up 64%, and reflect the merged company results versus the prior year period which reflected only legacy SWM results. Organic sales increased 6%, or 12% excluding negative currency impacts, driven primarily by price increases, and comparable Adjusted Operating Profit increased 28% (see non-GAAP reconciliations). Strong double-digit sales growth in release liners and protective solutions, as well as gains in filtration led the portfolio. Price increases exceeded inflationary pressures across ATM, delivering margin expansion versus prior year. While costs for certain raw materials, such as polypropylene resin have moderated, energy costs have risen substantially since mid-year, particularly in Europe, and are expected to remain elevated in the near-term; the Company continues to implement price increases and surcharges in response to energy and other inflationary pressures. On a comparable basis, including the legacy Neenah operations, ATM segment adjusted operating margin expansion would have been approximately 240 basis points, which is greater than the expansion shown in the table below (see non-GAAP reconciliations) that reflects only the legacy SWM results for the prior year period.

    (In millions; unaudited)

    Three Months Ended September 30,

     

     

    2022

     

     

    2021

     

    Change

     

    2022

     

     

    2021

     

    Net Sales

    $

    426.1

     

    $

    260.1

     

    $

    166.0

     

     

     

     

    Operating Profit & Margin %

    $

    31.5

     

    $

    15.9

     

     

    15.6

     

    7.4

    %

     

    6.1

    %

    Adjusted Operating Profit & Margin %

    $

    49.8

     

    $

    27.2

     

     

    22.6

     

    11.7

    %

     

    10.5

    %

    Adjusted EBITDA & Margin %

    $

    62.2

     

    $

    34.4

     

     

    27.8

     

    14.6

    %

     

    13.2

    %

    Fiber-Based Solutions (FBS) segment sales were $248.0 million, up 101%, and reflect the merged company results versus the prior year period which reflected only legacy SWM results. Organic sales growth was 7%, or 12% excluding negative currency impacts, driven primarily by price increases, and comparable Adjusted Operating Profit increased 6% (see non-GAAP reconciliations). Double digit sales growth in packaging and specialty papers led the portfolio. Price increases exceeded inflationary pressures for the segment. Energy costs have risen substantially since mid-year, particularly in Europe, and are expected to remain elevated in the near-term; the Company continues to implement price increases and surcharges in response. On a comparable basis, including the legacy Neenah operations, FBS segment adjusted operating margin would have been approximately equal (see non-GAAP reconciliations) in both periods versus the contraction shown in the table below that reflects only the legacy SWM results for the prior year period.

    (In millions; unaudited)

    Three Months Ended September 30,

     

     

    2022

     

     

    2021

     

    Change

     

    2022

     

     

    2021

     

    Net Sales

    $

    248.0

     

    $

    123.5

     

    $

    124.5

     

     

     

     

    Operating Profit & Margin %

    $

    27.8

     

    $

    24.0

     

     

    3.8

     

    11.2

    %

     

    19.4

    %

    Adjusted Operating Profit & Margin %

    $

    36.9

     

    $

    26.4

     

     

    10.5

     

    14.9

    %

     

    21.4

    %

    Adjusted EBITDA & Margin %

    $

    49.0

     

    $

    32.3

     

     

    16.7

     

    19.8

    %

     

    26.2

    %

    Unallocated expenses reflected the merged Company expenses in the quarter compared to only legacy SWM expenses in the prior year period. The Company generated early-stage synergy savings, but also incurred expenses to remediate the cybersecurity incident and merger-related expenses.

    (In millions; unaudited)

    Three Months Ended September 30,

     

     

    2022

     

     

     

    2021

     

     

    Change

     

    2022

     

    2021

    Operating Expense & % of Sales

    $

    (73.2

    )

     

    $

    (16.9

    )

     

    (56.3

    )

     

    (10.9) %

     

    (4.4) %

    Adjusted Operating Expense & % of Sales

    $

    (21.2

    )

     

     

    (13.6

    )

     

    (7.6

    )

     

    (3.1) %

     

    (3.5) %

    Adjusted EBITDA & Margin %

    $

    (18.2

    )

     

     

    (11.9

    )

     

    (6.3

    )

     

    (2.7) %

     

    (3.1) %

    Interest expense was $23.8 million, versus $15.3 million in the prior year period which reflected only the legacy SWM results. The increase was due to the merger and related incremental expense of assuming existing debt on the legacy Neenah balance sheet, as well as higher interest rates on floating rate debt versus the prior year.

    Taxes were 32.6% during third quarter 2022 and reflects the non tax-deductibility of a significant portion of expenses related to the closing of the Neenah merger. The Company expects a more normalized tax rate (excluding the impact of non-GAAP adjustment items) in the low 20% range going forward.

    Non-GAAP Adjustments reflect items included in GAAP operating profit, income, and EPS, but excluded from Adjusted Operating Profit, income, and EPS (see non-GAAP reconciliation tables for additional details). The most significant adjustments to third quarter 2022 results were as follows:

    • $0.36 per share of purchase accounting expenses (purchase accounting expenses reflect primarily ongoing non-cash intangible asset amortizations associated with mergers and acquisitions)
    • $0.78 per share of expenses related to the Neenah merger, which included closing costs and associated third-party fees, integration, and severance expenses
    • $0.08 per share related to incurred costs to remediate the cybersecurity incident

    Cash Flow, Debt, & Dividend

    Year-to-date 2022 cash provided by operating activities was $17.2 million, which included significant and largely non-recurring merger transaction, severance, and integration related costs, as well as a working capital outflow of $80.9 million driven by sales growth and higher cost inventories. Year-to-date capital spending and software costs totaled $38.6 million, resulting in negative free cash flow of $21.4 million. The Company expects a significant working capital improvement during the fourth quarter of 2022 related to enhancements of its working capital programs.

    Total debt was $1,828.5 million as of September 30, 2022 and total cash was $82.3 million, resulting in net debt of $1,746.2 million. Pursuant to the terms of the Company’s credit agreement, net debt to adjusted EBITDA was 4.2x as of September 30, 2022. Net leverage is defined in the Company’s credit agreement, and includes EBITDA adjustments for certain expected cost synergies. Total liquidity of approximately $389 million consisted of $82 million of cash and $307 million of revolver availability. The Company’s debt matures on a staggered basis between 2026 and 2028.

    The Company announced a quarterly cash dividend of $0.40 per share. The dividend will be payable on December 16, 2022 to stockholders of record as of November 25, 2022.

    Conference Call

    Mativ will hold a conference call to review third quarter 2022 results with investors and analysts at 8:30 a.m. Eastern time on Thursday, November 10, 2022. The earnings conference call will be simultaneously broadcast over the Internet at http://ir.mativ.com. To listen to the call, please go to the Company’s website at least 15 minutes prior to the call to register and to download and install any necessary audio software. For those unable to listen to the live broadcast, a replay will be available on the Company’s website shortly after the call.

    Mativ will use a presentation in conjunction with its conference call. The presentation can be found on the Company’s website under the Investor Relations section in advance of the earnings conference call. The presentation can also be accessed via the earnings conference call webcast.

    About Mativ

    Mativ Holdings, Inc. is a global leader in specialty materials headquartered in Alpharetta, Georgia. The Company offers a wide range of critical components and engineered solutions to solve our customers’ most complex challenges. With over 7,500 employees worldwide, we manufacture on four continents and generate sales in more than 100 countries. The Company’s two operating segments, Advanced Technical Materials and Fiber-Based Solutions, target premium applications across diversified and growing end-markets, from filtration to healthcare to sustainable packaging. Our broad portfolio of technologies combines polymers, fibers, and resins to optimize the performance of our customers’ products across multiple stages of the value chain. Our leading positions are a testament to our best-in-class global manufacturing, supply chain, and materials science capabilities. We drive innovation and enhance performance, finding potential in the impossible.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to the safe harbor created by that Act and other legal protections. Forward-looking statements include, without limitation, those regarding EPS and other financial guidance, acquisition integration and performance, growth prospects, future end-market trends, the future effects of supply chain challenges and price increases, future cash flows, net leverage, purchase accounting impacts, effective tax rates, planned investments, impacts of the COVID-19 pandemic on our operations, profitability, and cash flow, the expected benefits and accretion of the Neenah merger and Scapa acquisition and integration and other statements generally identified by words such as “believe,” “expect,” “intend,” “guidance,” “plan,” “forecast,” “potential,” “anticipate,” “confident,” “project,” “appear,” “future,” “should,” “likely,” “could,” “may,”, “will”, “typically,” and similar words.

    These forward-looking statements are prospective in nature and not based on historical facts, but rather on current expectations and on numerous assumptions regarding the business strategies and the environment in which Mativ will operate in the future and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. No assurance can be given that such expectations will prove to have been correct and persons reading this presentation are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this press release. These statements are not guarantees of future performance and involve certain risks and uncertainties, and assumptions that may cause actual results to differ materially from our expectations as of the date of this release. These risks include, among other things, the following factors: risks associated with pandemics and other public health emergencies, including the continued impact of, and the governmental and third party response to, the COVID-19 pandemic and its variant strains; changes in sales or production volumes, pricing and/or manufacturing costs of paper, specialty packaging, combustible products for the tobacco industry (including conventional papers and certain reduced-risk products) and hemp-based fibers for emerging alternative solutions in our FBS segment. Additionally; competition and changes in ATM end-market products due to changing customer demands; risks associated with the implementation of our strategic growth initiatives, including diversification, and the Company’s understanding of, and entry into, new industries and technologies; changes in the source and intensity of competition in our commercial segments; our ability to attract and retain key personnel, including as a result of the merger, labor shortages, labor strikes, stoppages or other disruptions; weather conditions, including potential impacts, if any, from climate change, known and unknown, and natural disasters or unusual weather events; seasonal or cyclical market and industry fluctuations which may result in reduced net sales and operating profits during certain periods; changes in raw material and energy availability, increases in commodity prices and lack of availability of such commodities, including energy, wood pulp, resins, and other key raw materials, which could impact the sales and profitability of our products; adverse changes in the filtration, release liners, protective solutions, construction and infrastructure and healthcare sectors impacting key ATM segment customers; increases in operating costs due to inflation and continuing increases in the inflation rate or otherwise, such as labor expense, compensation and benefits costs; changes in employment, wage and hour laws and regulations in the U.S., France and elsewhere, including the loi de Securisation de l’emploi in France, unionization rule and regulations by the National Labor Relations Board in the U.S., equal pay initiatives, additional anti-discrimination rules or tests and different interpretations of exemptions from overtime laws; the impact of tariffs, and the imposition of any future additional tariffs and other trade barriers, and the effects of retaliatory trade measures; existing and future governmental regulation and the enforcement thereof that may materially restrict or adversely affect how we conduct business and our financial results; new reports as to the effect of smoking on human health or the environment; changes in general economic, financial and credit conditions in the U.S., Europe, China and elsewhere, including the impact thereof on currency exchange rates (including any weakening of the Euro and Real) and on interest rates; the phasing out of USD LIBOR rates after 2023 and the replacement with SOFR; changes in the manner in which we finance our debt and future capital needs, including potential acquisitions; supply chain disruptions, including the failure of one or more material suppliers, including energy, specialty fiber, resin, pulp and other raw material suppliers, to supply materials as needed to maintain our product plans and cost structure; international conflicts and disputes, such as the ongoing conflict between Russia and Ukraine, which restrict our ability to supply products into affected regions, due to the corresponding effects on demand, the application of international sanctions, or practical consequences on transportation, banking transactions, and other commercial activities in troubled regions; compliance with the FCPA and other anti-corruption laws or trade control laws, as well as other laws governing our operations; the pace and extent of further international adoption of LIP cigarette standards and the nature of standards so adopted; risks associated with our 50%-owned, non-U.S. joint ventures relating to control and decision-making, compliance, accounting standards, transparency and customer relations, among others; a failure in our risk management and/or currency or interest rate swaps and hedging programs, including the failures of any insurance company or counterparty; the number, type, outcomes (by judgment or settlement) and costs of legal, tax, regulatory or administrative proceedings, litigation and/or amnesty programs, including those in Brazil, France and Germany; the outcome and cost of the LIP-related intellectual property litigation against Glatz in Europe; risks associated with our technological advantages in our intellectual property and the likelihood that our current technological advantages are unable to continue indefinitely; risks associated with acquisitions, dispositions, strategic transactions and global asset realignment initiatives of Mativ; costs and timing of implementation of any upgrades or changes to our information technology systems; failure by us to comply with any privacy or data security laws or to protect against theft of customer, employee and corporate sensitive information; the impact of cybersecurity risks related to breaches of security pertaining to sensitive Company, customer or vendor information, as well as breaches in the technology that manages operations and other business processes; changes in tax rates, the adoption of new U.S. or international tax legislation or exposure to additional tax liabilities; changes in construction and infrastructure spending and its impact on demand for certain products; potential loss of consumer awareness and demand for acquired companies’ products if it is decided to rebrand those products under the Company’s legacy brand names; failing to fully realize anticipated cost savings and other anticipated benefits of the Neenah merger when expected or at all; business disruptions from the proposed Neenah merger that will harm the Company’s business, including current plans and operations; potential adverse reactions or changes to business relationships resulting from the Neenah merger, including as it relates to the Company’s ability to successfully renew existing client contracts on favorable terms or at all and obtain new clients; the substantial indebtedness Mativ has incurred and assumed in connection with the Neenah and the need to generate sufficient cash flows to service and repay such debt; the possibility that Mativ may be unable to achieve expected synergies and operating efficiencies within the expected time-frames or at all and to successfully integrate Neenah’s operations with those of Mativ; uncertainty as to the long-term value of the common stock of Mativ, including the dilution caused by Mativ’s issuance of additional shares of its common stock in connection with the Neenah merger; and other factors described elsewhere in this document and from time to time in documents that we file with the U.S. Securities and Exchange Commission (the “SEC”).

    All forward-looking statements made in this document are qualified by these cautionary statements. Forward-looking statements herein are made only as of the date of this document, and Mativ undertakes no obligation, other than as may be required by law, to update or revise any forward-looking or cautionary statements to reflect changes in assumptions, the occurrence of events, unanticipated or otherwise, or changes in future operating results over time or otherwise. For a more detailed discussion of these factors, also see the information under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Mativ’s most recent annual reports on Form 10-K for the year ended December 31, 2021, under the caption “Risk Factors” in Mativ’s Registration Statement on Form S-4 filed in connection with the Neenah merger, and any material updates to these factors contained in any of Mativ’s future filings with the SEC. The discussion of these risks is specifically incorporated by reference into this release. The financial results reported in this release are unaudited.

    Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance unless expressed as such and should only be viewed as historical data.

    Contacts

    Andrew Wamser

    Chief Financial Officer

    +1-770-569-4271

    or

    Mark Chekanow, CFA

    Director of Investor Relations

    +1-770-569-4229

    Website: http://www.mativ.com

    Read full story here

  • Global Cannabis-infused Edibles Market Report 2022: Growing Cannabis Legalization and Elevating Popularity of Home-Grown Cannabis Driving Sector – ResearchAndMarkets.com

    DUBLIN–(BUSINESS WIRE)–The “Global Cannabis-infused Edibles Market (2022-2027) by Product, Raw Material, Source, Distribution Channel, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.

    The Global Cannabis-infused Edibles Market is estimated to be USD 4.37 Bn in 2022 and is expected to reach USD 9.81 Bn by 2027, growing at a CAGR of 17.56%

    Market Dynamics

    Drivers

    • Growing Cannabis Legalization and Elevating Popularity of Home-Grown Cannabis
    • Rising Millennial Population Demanding Cannabis-Infused Edibles
    • Increasing Penetration in Bakery, Confectionery, and Gummies

    Restraints

    • Poor Blending and Inaccurate Dosing Resulting in Dangerous Consequences

    Opportunities

    • New Product Development Related to Cannabis-Infused Foods and Beverages
    • Rise of Alcohol Companies in the Cannabis Edibles Market

    Challenges

    • Production and Commercialization of Cannabis Subject to Varying International Laws

    Market Segmentations

    The Global Cannabis-infused Edibles Market is segmented based on Product, Raw Material, Source, Distribution Channel, and Geography.

    • By Product, the market is classified into Baked Products, Chocolates & Bars, Drinks, Gum & Sprays, and Sugar Candies.
    • By Raw Material, the market is classified into Hemp CBD Oil and Marijuana CBD Oil.
    • By Source, the market is classified into Inorganic and Organic.
    • By Distribution Channel, the market is classified into Offline Mode and Online Mode.
    • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

    Competitive Quadrant

    The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

    Ansoff Analysis

    The report presents a detailed Ansoff matrix analysis for the Global Cannabis-infused Edibles Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

    The analyst analyses the Global Cannabis-infused Edibles Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

    Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

    Why buy this report?

    • The report offers a comprehensive evaluation of the Global Cannabis-infused Edibles Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
    • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
    • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
    • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
    • The report also contains a competitive analysis using Positioning Quadrants, the analyst’s competitive positioning tool.

    Report Highlights:

    • A complete analysis of the market, including the parent industry
    • Important market dynamics and trends
    • Market segmentation
    • Historical, current, and projected size of the market based on value and volume
    • Market shares and strategies of key players
    • Recommendations to companies for strengthening their foothold in the market

    Key Topics Covered:

    1 Report Description

    2 Research Methodology

    3 Executive Summary

    4 Market Dynamics

    5 Market Analysis

    6 Global Cannabis-infused Edibles Market, By Product

    7 Global Cannabis-infused Edibles Market, By Raw Material

    8 Global Cannabis-infused Edibles Market, By Source

    9 Global Cannabis-infused Edibles Market, By Distribution Channel

    10 Americas’ Cannabis-infused Edibles Market

    11 Europe’s Cannabis-infused Edibles Market

    12 Middle East and Africa’s Cannabis-infused Edibles Market

    13 APAC’s Cannabis-infused Edibles Market

    14 Competitive Landscape

    15 Company Profiles

    16 Appendix

    Companies Mentioned

    • Atlas Growers, Ltd.
    • Aurora Cannabis, Inc.
    • Baked Bros
    • Bhang Corp.
    • Cannabinoid Creations
    • Cannabis Energy Drink
    • Canopy Growth Corp.
    • Charlotte’s Web Holdings, Inc.
    • Cresco Labs, LLC
    • Curaleaf Holding, Inc.
    • CV Sciences, Inc.
    • Dixie Group, Inc.
    • Elixinol, LLC
    • Evergreen herbal, Ltd.
    • Heineken N.V.
    • Joy Organics Private, Ltd.
    • Kaneh Co
    • Kats Botanicals
    • Kaya Holdings, Inc.
    • Kazmira, LLC
    • Kiva Confections
    • Koios Beverage, Corp
    • Medically Correct, LLC
    • Medix CBD
    • Organigram Holdings, Inc.
    • Plus Products
    • Tilray, Inc.

    For more information about this report visit https://www.researchandmarkets.com/r/ze5r7k

    Contacts

    ResearchAndMarkets.com

    Laura Wood, Senior Press Manager

    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470

    For U.S./ CAN Toll Free Call 1-800-526-8630

    For GMT Office Hours Call +353-1-416-8900

  • Cookies Welcomes East Coast Cannabis Brand Gumbo Into Cookies Family, Debuts New Cultivar in CA

    Black-Owned Cannabis Company Gumbo Becomes 8th Cookies Brand, With Hot Cultivar Madison Square Gumbo Launching Across California

    SAN FRANCISCO–(BUSINESS WIRE)–A new partnership between international cannabis lifestyle brand Cookies and trend-setting cannabis company Gumbo is bringing a new cultivar to all Cookies and Lemonnade locations across California beginning Monday, Nov. 14. The highly anticipated, exclusive Madison Square Gumbo cultivar—a hybrid of Cookies & Cream x Secret Weapon yielding euphoric, uplifting effects, and fruity, earthy flavors and aromas—represents the first of many anticipated collaborations between Cookies and Gumbo.

    “I’m proud to finally be launching Gumbo on the rec market,” said Berner, Co-Founder and CEO of Cookies. “I remember seeing Gumbo everywhere—it reminded me of how I popped Cookies off. When I met Luka and his wife, I loved that they were so dedicated to doing this right. Even more attractive than the brand presence or them being such cool people was the purpose behind the brand. We need to keep people from the game, in the game.”

    Founders Karim “Luka Brazi” Butler and Alexis Major started Gumbo to nurture community-based wealth through creativity and culture, and to help people to achieve a sense of ease and wellness through top-tier cultivars and the power of the cannabis plant. As one of the first Black-owned cannabis companies in New York, Butler and Major hope their continued success creates aspirations within the community in regards to ownership.

    “Uniting Cookies and Gumbo just made sense—we all share the same values when it comes to helping others, producing quality products and expanding our footprint, while still keeping it true to the culture,” said Major, Co-Founder of Gumbo Brands.

    Future launches will build on Gumbo’s success with signature strains such as Jambalaya and Ghoulies, which received endorsements from musicians like Meek Mill, Migos, Dave East and Fabolous. As part of the Cookies family, Gumbo joins renowned brands Lemonnade, Run The Jewels, Collins Ave, Powerzzzup, Grandiflora and Minntz.

    “Cookies has been a highly recognized and respected player in the cannabis industry for the last decade, so we’re incredibly excited about what’s ahead for Gumbo in California and beyond,” said Butler, Co-Founder of Gumbo Brands.

    The initial drop of Madison Square Gumbo includes eighths and pre-rolls beginning Friday, Nov. 11 at Cookies Hayward, Saturday, Nov. 12 at Cookies Maywood and at all Cookies and Lemonnade stores in California on Monday, Nov. 14. Learn more: cookies.co

    About Cookies

    Cookies, founded in 2010 by Billboard-charting rapper and entrepreneur Berner and Bay Area breeder and cultivator Jai, is the most globally recognized cannabis company in the world. Cookies values the power of the plant and focuses on creating game-changing genetics. The company offers a collection of over 70 proprietary cannabis cultivars and more than 2,000 products. Cookies also actively works to enrich communities disproportionately impacted by the War on Drugs through advocacy and social equity initiatives. Headquartered in San Francisco, the company opened its first retail store in 2018 in Los Angeles, and has since expanded to over 55 retail locations in 17 markets across 5 countries. Cookies was named one of America’s Hottest Brands of 2021 by AdAge; the first cannabis brand to ever receive this accolade. To learn more about Cookies, visit cookies.co, and to learn more about Cookies CBD, visit https://shop.cookies.co/

    About Gumbo Brands

    Gumbo Brands is a new revolutionary cannabis and lifestyle company founded by the Black-owned entrepreneurial power-couple, Karim Butler and Alexis Major. The multi-million-dollar company exploded within the past few years with its expansion into the media world as a brand sponsor of the award-winning Drink Champs podcast and by working with top artists such as Meek Mill, Lil Meech, NORE, Takeoff of the Migos, Dave East, Fabolous and others. Gumbo Brands’ main focus is making a difference, building wealth and sharing knowledge within the Black and Brown communities via give-back initiatives, and alliances within the sports and entertainment industries.

    Contacts

    Cookies Media Contact:
    Martha N. Marshall

    Grasslands: A Journalism-Minded Agency

    martha@mygrasslands.com
    703-474-1420

    Gumbo Media Contact:
    Francoise Blanchette

    MCM-PR

    Francoise@MCM-PR.com
    646-570-7938

  • CannPack Digital Packaging Forum Announces Free December Online Educational Event

    The free virtual event focuses on best practices in cannabis packaging industry amidst heightened focus on regulation, sustainability and safety

    ANAHEIM, Calif.–(BUSINESS WIRE)–#CannPackCannPack, the leading conference in cannabis processing and packaging, announced it is hosting the inaugural CannPack Digital Packaging Forum on Dec. 7-8. The free virtual event offers two half days of educational sessions focusing on cannabis packaging best practices, child-resistance packaging, sustainability, and packaging design innovations.

    “The CannPack Digital Packaging Forum is the only dedicated online opportunity for cannabis growers, manufacturers and designers to work together and create solutions for packaging challenges in the industry,” says Susan Frederick, Event Leader. “The two-day agenda will include panel discussions, thoughtful keynotes and case study presentations that specifically target current trends, manufacturing advancements and regulatory needs in the industry.”

    A full list of the presentations for the CannPack Digital Packaging Forum can be accessed at the CannPack website. The digital forum begins at 10 a.m. PT and ends at noon PT on both days. Lisa Pierce, Executive Editor of Packaging Digest, will serve as the moderator for both days of the show, including sessions with Hippo Premium Packaging, AssurPack, DIZPOT, and Tourmaline Enterprises.

    The CannPack Digital Packaging Forum also will offer a preview of the live CannPack Conference, returning to WestPack at Informa Markets Engineering West in Anaheim, California, on Feb. 8, 2023. Those attending the CannPack Conference can use the digital forum to engage with other packaging professionals around the country and generate new business-to-business leads​ to build their presence for the West show.

    Visitors planning to attend the CannPack Conference in Anaheim also can access the five-in-one co-located manufacturing West Coast event at www.imengineeringwest.com. Registrants for the Anaheim expo are encouraged to plan ahead through the Smart Event digital platform to connect in the weeks prior leading up to the show.

    About Informa Markets – Engineering:

    Informa Markets’ Engineering portfolio is the leading B2B event producer, publisher, and digital media business for the world’s $3 trillion advanced, technology-based manufacturing industry. Our print and electronic products deliver trusted information to the engineering market and leverage our proprietary 1.3 million name database to connect suppliers with buyers and purchase influencers. We produce more than 50 events and conferences in a dozen countries, connecting manufacturing professionals from around the globe. The Engineering portfolio is organized by Informa, the world’s leading exhibitions organizer that brings a diverse range of specialist markets to life, unlocking opportunities and helping them thrive 365 days of the year. For more information, visit www.informamarkets.com, and keep up to date with the latest Informa Markets engineering news on Twitter, Facebook and LinkedIn.

    About Informa Markets:

    Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. We provide marketplace participants around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, targeted digital services and actionable data solutions. We connect buyers and sellers across more than a dozen global verticals, including Pharmaceuticals, Food, Medical Technology and Infrastructure. As the world’s leading market-making company, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.

    Contacts

    Gabby McMillen Bailey

    Informa Markets Engineering
    pr.ime@informa.com

  • Akanda Announces Arrival of First Shipment and Sales of Medical Cannabis to Germany

    • Akanda announces first export shipment to Germany of high THC indoor cultivated premium cannabis from its Portugal-based operation
    • Akanda is enabling sales of medical cannabis for patients across Germany
    • Akanda stands ready to serve legal adult-use markets in Europe once established

    LONDON–(BUSINESS WIRE)–International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) expects to take a leading position in the fast-growing German medical cannabis market, as it sees its first export shipment arrive from its Portugal-based operation and announces the first sale has been achieved, solidifying the company as operationally profitable in the market. Akanda recently entered into an agreement to deliver at least 1,000 kilograms of high-grade medical cannabis flower to Germany through the Cansativa platform. The deal ranks as one of the largest supply agreements in the European medical cannabis industry. Cansativa is also the only company in Germany permitted to distribute domestically grown cannabis.


    “This is an impressive milestone for Akanda’s push into the German medical cannabis market. The successful arrival of our first shipment of flower to supply patients through the Cansativa platform is an indication of the market’s demand for premium high THC medical cannabis,” commented Akanda’s CEO Tej Virk. “Our Portugal-based EU GMP-certified medical cannabis cultivation operation hosts a one-of-a-kind 20,000 square foot indoor premium cultivation site in Sintra and a 7 million square foot (180+ acres) outdoor site in Aljustrel. Akanda is dedicated to fulfilling supply agreements and delivering high THC, non-irradiated, premium quality standard medical cannabis flower to the market. Our premium medical cannabis flower has tested as high as 28% THC and the Sintra indoor facility has produced approximately 1,200kg to date.”

    Germany’s health minister recently released initial guidelines for adult-use legalization in the country. “We applaud the German government’s push forward in maintaining their leadership position in Europe regarding cannabis regulation. Federal legalization could result in crucial consumer safety benefits and economic stimulus, as evidenced by the experience in Canada and at the state level in the United States. While questions remain around the final implementation, their action serves as a beacon for other European countries considering legalization, such as Portugal. We stand ready to supply these future adult-use markets with premium quality cannabis flower when laws become established,” continued Virk.

    Recently, Akanda has also announced an exclusive license agreement with the iconic international cannabis lifestyle brand Cookies. The multi-year agreement enables Akanda to pursue the current medical and future adult-use opportunities in Europe with arguably one of the world’s best-known cannabis brands and the highest-quality genetics. Akanda intends to initially produce EU GMP certified Cookies branded high THC medical cannabis products at its flagship indoor premium cultivation and manufacturing facility in Sintra. The company is readying to become a dominant player as one of the world’s highest quality EU GMP cultivators, targeting a 10% market share in the German medical cannabis market and the future regulated adult-use market once it becomes a reality.

    About Akanda Corp.

    Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high-quality and affordable products. Akanda’s portfolio includes Holigen, a Portugal-based cultivator, manufacturer, and distributor with a prized EU GMP -certified premium indoor grow facility; and CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK. The Company’s seed-to-patient supply chain also includes partnerships with California-based Cookies, the most globally recognized cannabis company in the world; Cansativa Group, a leading importer and distributor of medical cannabis in Europe; and Cellen Life Sciences’ Leva Clinic, one of the first fully digital pain clinics in the UK.

    Connect with Akanda: Email | Website | LinkedIn | Twitter | Instagram

    Cautionary Note Regarding Forward-Looking Information and Statements

    This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Akanda’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Akanda’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking information may relate to anticipated events or results including, but not limited to business strategy, product development and sales and growth plans. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Akanda does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

    Contacts

    Investor Contact
    ir@akandacorp.com

    Media Contact
    Imogen Saunders

    Irvine Partners

    imogen@irvinepartners.co.uk